On October 20,

National-level Event in Biotechnology—

2021 China Biotech Innovation Conference (3rd)

Opened in CDHT

Nearly 30 academicians, more than 300 authoritative experts

more than 1000 experts and scholars

as well as nearly 20 of the world's top 500 multinational pharmaceutical companies

and more than 50 representatives of well-known pharmaceutical enterprises at home and abroad gathered in Chengdu

to discuss the new development of biotechnology in China.

 

 

       With the theme of "self-reliance and self-improvement in science and technology to promote people's health", this conference will last for three days, with an opening ceremony, 17 sub-sessions and 3 closed-door meetings. Focusing on the five main sections of policy, technology & industry, base platform & talents, capital and sci-tech achievements transformation, it will carry out in-depth exchanges and discussions through academic reports, special seminars, important release, achievement display and other activities, comprehensively display China's biotechnology development achievements during the 13th Five Year Plan period, jointly plan the biotechnology development path during the 14th Five Year Plan period, and explore a new pattern of biomedical innovation and development.

 

       B I O T I A N F U

       Nearly 30 Academicians and Over 300 Authoritative Experts Gathering in Chengdu

       Six Academicians Releasing Theme Reports and New Medical Books on Site

       —  

       It is worth mentioning that the number of academicians and experts at this conference is the highest ever, attracting nearly 30 academicians, more than 300 authoritative experts and more than 1000 experts and scholars to Chengdu.

 

       Including Shi Bi, academician of Chinese Academy of Engineering, Zhan Qimin, academician of the Chinese Academy of Engineering, Jin Li, academician of the Chinese Academy of Engineering, Lin Dongxin, academician of the Chinese Academy of Engineering, Jin Ningyi, academician of the Chinese Academy of Engineering, Jiang Hualiang, academician of the Chinese Academy of Sciences, Wu Zhaohui, academician of the Chinese Academy of Engineering, Chen Jian, academician of the Chinese Academy of Engineering, Liu Liang, academician of the Chinese Academy of Engineering, Zhao Zhentang, academician of Chinese Academy of Engineering, Yao Bin, academician of Chinese Academy of Engineering, and other industry leaders.

 

       In addition, the conference also attracted nearly 20 of the world's top 500 multinational pharmaceutical enterprises and more than 50 well-known pharmaceutical enterprises at home and abroad, including Novartis, Pfizer, AstraZeneca, Sanofi, Bayer and Allergan, to gather in Chengdu to talk about China's biotechnology innovation and development.

 

 

       At the opening ceremony of the conference, four academicians were invited to share their thematic reports from different angles, discuss the latest frontier in the field of biotechnology with the guests, and look forward to the future development trend.

 

       He Fuchu, academician of the Chinese Academy of Sciences, demonstrated in his special report entitled Big Science Program and China's Mission that the big science program is the latest research paradigm that integrates engineering methods and planning means, gathers the strength of scientific and technological resources, and solves major scientific propositions, fully demonstrating that the big science program is the key factor for the rapid evolution of scientific research from traditional "small manual workshop" to modern large-scale "workshop".

       In the special report entitled Brain Science and Brain-like Artificial Intelligence, Pu Muming, academician of the Chinese Academy of Sciences, shared the innovative application of the basic principles of brain science in the development of brain-like artificial intelligence, which has important guiding significance for the development of brain-like artificial intelligence.

       Wang Guangji, academician of the Chinese Academy of Engineering, shared the pharmacokinetic and pharmacodynamic research theories and achievements of cell therapy products in the special report entitled Exploration on Druggability of Cell Therapy Products Based on Pharmacokinetic and Pharmacodynamic Research, and put forward the key issues to be addressed in the current druggability research, which laid a foundation for further accelerating the standardized development of cell therapy industry.

       In the special report entitled Thoughts on the Development of Traditional Chinese Medicine, Zhang Boli, academician of Chinese Academy of Engineering, explained the concept of traditional Chinese medicine from the mechanism to the clinical application, and shared the indispensable role played by traditional Chinese medicine in combating the COVID-19 epidemic.

 

       At the opening ceremony, there are three academicians released their new medical reports:

 

       Zhang Boli, academician of the Chinese Academy of Engineering, released the 2020 Report on Research and Development of Traditional Chinese Medicine, which systematically reviews the development status and achievements of traditional Chinese Medicine under the pilotage of national policies since 2020, so as to promote the research and development of traditional Chinese medicine in the 14th Five-Year Plan, serve the national strategy and economic and social development, and provide reference for the development of traditional Chinese medicine in the next stage.

       Wei Yuquan, academician of the Chinese Academy of Sciences, released the 2021 China Life Science and Biotechnology Development Report, which summarizes the frontier progress in the field of life science in 2020, focuses on emerging hot spots in the field of biotechnology, and analyzes the industrial development trend, demonstrating that China's life science and biotechnology are moving towards a new stage of systematization, engineering and digitization.

       Lu Lin, academician of the Chinese Academy of Sciences, released the 2021 China Clinical Medical Research Development Report, which analyzes the current situation and trend of clinical medicine research at home and abroad in 2020, summarizes the policies and regulations related to clinical medicine research at home and abroad, and displays the important progress and achievements of clinical medicine research in China.

 

       B I O T I A N F U

       2020 China Biomedical Industrial Park Ranking Released

       CDHT Among First Legion in Comprehensive Competitiveness

       —  

Since 2013, China National Center for Biotechnology Development has carried out competitiveness evaluation and analysis of China bioindustry parks for 7 times, continuously focusing on the development of biological medicine industry in China.

 

       China National Center for Biotechnology Development releases the competitiveness evaluation of the park every year, hoping to guide each park to learn from each other and promote the development of local industries.

                                                                                                                                           —Fan Ling, deputy Director of China National Center for Biotechnology Development

 

 

       At the opening ceremony, the long-awaited 2021 China Biomedical Industrial Park Competitiveness Evaluation and Analysis Report was officially released, and the 2020 China Biomedical Industrial Park Competitiveness Ranking List was announced on the spot.

 

       The ranking list is divided into single competitiveness and comprehensive competitiveness. In the ranking of comprehensive competitiveness, CDHT, Suzhou Industrial Park, Zhongguancun National Independent Innovation Demonstration Zone and Shanghai Zhangjiang High-tech Industrial Development Zone top the rankings jointly.

 

       The Report comprehensively and systematically compares the data of the parks investigated, and ranks the competitiveness of 121 national-level high-tech zones, 81 national-level economic development zones, 13 provincial-level and other parks (a total of 215 parks) based on five primary index systems (environmental competitiveness, industrial competitiveness, technical competitiveness, talent competitiveness and cooperative competitiveness) and 39 secondary index systems (such as output value, growth rate and R&D investment of biomedical industry).

 

 

       B I O T I A N F U

       17 Sub-sessions and 3 Closed-door Meetings

       to Discuss for Common Development

       —  

 

 

       In addition, the conference also set up 17 sub-sessions and 3 closed-door meetings, covering the latest frontier and future trends of biotechnology including biotechnology fields such as innovative drug R&D, clinical medical research, medical equipment, biological frontier technology, green bio-manufacturing, biotech drug development, tissue and organ aging and repair, food nutrition and safety, prevention and treatment of major diseases with traditional Chinese medicine, poverty alleviation in traditional Chinese medicine industry and sci-tech innovation. Many academicians, experts and enterprise representatives talked about the new trend of biomedicine in the future.

 

 

       In addition to the professional sub forums, the conference also set up Young Scientists Forum, Women Scientists Forum and Biotechnology Young Talents Seminar to encourage young talents and women in the industry to show themselves and learn from each other.

 

       BIOTIANFU

       Building High-quality Development Highland of Biomedicine

       CDHT Biotechnology Innovation "Accelerating"

       —  

       Many leading biomedical enterprises in Chengdu, such as WestVac Biopharma Co., Ltd. from CDHT, also attended the meeting.

 

       WestVac, a unicorn enterprise valued at more than RMB 6 billion seven months after its establishment, has a research team led by Professor Wei Yuquan, an academician of Chinese Academy of Sciences and the Director of the State Key Laboratory of Biotherapy in West China Hospital of Sichuan University. It is a biomedical company specializing in vaccine R&D, production and immunotherapy. In the eyes of academician Wei Yuquan, CDHT has achieved remarkable results in leading the construction of industrial functional zones with biomedical industry ecosystem, which provides strong support and confidence for the development of enterprises.

 

       After the outbreak of the COVID-19 epidemic, CDHT continued to paid close attention to the progress of team vaccine research, carried out achievements transformation and enterprise incubation in advance, which directly promoted the establishment of WestVac. On the other hand, CDHT integrated all forces through early investment, building plants, recommended financing, etc. to fully help WestVac to grow rapidly, and promoted the company to achieve leapfrog development, and realize assets leverage of nearly 200 times.

                                                                                —Wei Yuquan, academician of Chinese Academy of Sciences and Director of the State Key Laboratory of Biotherapy in West China Hospital of Sichuan University

 

 

       WestVac is a miniature of the rapid development of bio-industry in CDHT. CDHT adheres to building an industrial ecosystem with “Five-chain Integration", aiming at the original innovation from 0 to 1, building a full-chain biotechnology service platform, and forming an industrial cluster of modern traditional Chinese medicine, chemical drugs, biological agents and medical equipment. It has gathered more than 3000 domestic and foreign well-known enterprises, and the industrial scale has maintained a 20% growth rate for four consecutive years.

 

Data

       Up to now, CDHT has successfully completed the first phase construction of the pilot demonstration base for national major scientific and technological achievements transfer and transformation in major new drug creation, broke through 29 key technologies, supported the domestic application of 437 new drug varieties, and gathered nearly 100 national talent teams, attracting a large number of high-energy level projects such as the West Operation Center of the Fortune 500 company GILEAD (the first investment project), and the second headquarters and the innovation center of the Fortune 500 company Boston Scientific. Among them, the Medical Innovation Center of Medtronic, the Western China Headquarters of AstraZeneca and other projects have been successfully put into service this year.

 

Next,

CDHT will further focus on the construction of innovation strategy source capacity,

give full play to the role and effectiveness of the "four schools" of talents,

strive to promote the implementation and transformation of sci-tech achievements,

Actively build the growth pole and power source of bio-industry integrated into the construction of the Chengdu-Chongqing Economic Circle.

 

 

 

Source: Bio-industry Development Bureau of CDHT